Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
ODYSSEE trial: what clinicians have said so far
PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients
- NCT02928523 ↗
- Completed
- MaaT Pharma
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ODYSSEE (acute myeloid leukemia undergoing intensive treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ODYSSEE so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 YouTube videos, typically up to 9 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Autologous Fecal Microbiota Transplantation
- Arms
- Autologous Fecal Microbiota Transplantation · Experimental
- Enrollment
- 20
- Primary outcomes
- Evaluation of AFMT efficacy in dysbiosis correction by measure of microbiota diversity
- Evaluation of AFMT efficacy in MDRB eradication based on bacterial culture
- Sponsor
- MaaT Pharma
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Results posted
- No
- Registry record
- NCT02928523 · updated Sep 9, 2020
Publications
linked from the registry- Malard F, Vekhoff A, Lapusan S, Isnard F, D'incan-Corda E, Rey J, Saillard C, Thomas X, Ducastelle-Lepretre S, Paubelle E, Larcher MV, Rocher C, Recher C, Tavitian S, Bertoli S, Michallet AS, Gilis L, Peterlin P, Chevallier P, Nguyen S, Plantamura E, Boucinha L, Gasc C, Michallet M, Dore J, Legrand O, Mohty M. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6. PubMed 34035290